Curated News
By: NewsRamp Editorial Staff
July 30, 2026
Instinct Bio Partners with Invitrx to Launch GENREVER in U.S., Boost Indonesia Regenerative Medicine
TLDR
- Instinct Bio gains competitive edge by leveraging INVITRX's U.S. GMP manufacturing to launch GENREVER in the premium U.S. cosmetics market.
- Instinct Bio and INVITRX signed an MOA to manufacture GENREVER cosmetics in the U.S. and supply exosomes for Indonesian clinics.
- This collaboration aims to advance regenerative medicine in Indonesia, potentially improving healthcare access and outcomes in a growing market.
- Instinct Bio and INVITRX expand a six-year raw material relationship into a strategic collaboration for cosmetics and cell processing.
Impact - Why it Matters
This collaboration matters because it bridges Japanese cosmetic innovation with U.S. GMP manufacturing, potentially setting a new standard for premium skincare. For consumers, it may bring high-quality, scientifically-backed products to the U.S. market. For the regenerative medicine field, the Indonesia initiative could expand access to advanced therapies like exosome treatments in emerging healthcare markets, driving global health equity and innovation.
Summary
Instinct Bio (Nasdaq: BIOT) has announced a strategic collaboration with Invitrx Therapeutics, Inc. to expand its GENREVER cosmetics brand into the U.S. and advance regenerative medicine initiatives in Indonesia. The agreement, formalized through a Memorandum of Agreement, leverages a six-year commercial relationship where Instinct Bio sourced raw materials from Invitrx. Under the proposed workstreams, Instinct Bio's subsidiaries will license the GENREVER trademark and contribute proprietary formulations, while Invitrx will manufacture the products at its U.S. GMP facility, positioning GENREVER as a premium Japanese brand in the U.S. market. Additionally, the companies plan to supply concentrated exosomes and conditioned media for clinics and an in-hospital cell processing center in Indonesia, aiming to establish a localized regenerative medicine platform in Southeast Asia.
The collaboration brings together Japanese product innovation, U.S. manufacturing capabilities, and regenerative medicine expertise. Tomoki Nagano, CEO of Instinct Bio, highlighted that this partnership creates a strong foundation for growth in the U.S. and Southeast Asia. The companies will negotiate definitive agreements while progressing regulatory assessments. Instinct Bio focuses on regenerative medicine and longevity technologies, while Invitrx operates a GMP facility producing cell-derived biological materials. This initiative could significantly impact the cosmetics and regenerative medicine sectors by blending premium branding with advanced biomanufacturing.
Forward-looking statements caution that definitive agreements are not guaranteed, and risks include regulatory approvals, market acceptance, and supply chain challenges. However, the existing relationship may facilitate coordination. The announcement was made via NEWMEDIAWIRE, and more information is available on Instinct Bio's website. This collaboration underscores a trend of cross-border partnerships in biotech, combining Asian brand heritage with U.S. manufacturing standards to address global markets.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Instinct Bio Partners with Invitrx to Launch GENREVER in U.S., Boost Indonesia Regenerative Medicine
